A percentage on a semaglutide page usually comes from a particular trial, not from a promise about every patient. Before using it to compare options, reconstruct the question the researchers asked. Who entered the study, which formulation did they receive, what did the comparison group receive, and when was weight measured? Those four details determine what the number can reasonably tell you.
Start with the actual STEP 1 experiment
STEP 1 randomized 1,961 adults with obesity, or overweight plus a qualifying condition, without diabetes. Participants received weekly subcutaneous semaglutide 2.4 mg or placebo alongside lifestyle intervention for 68 weeks. Mean weight change was −14.9% and −2.4%, respectively. These are group results for the studied regimen and population, not a guaranteed response to any product containing semaglutide.
The placebo group matters. It shows why the active-treatment group’s total change should not be described as entirely caused by the medicine. The investigators estimated a between-group treatment difference; that is a different quantity from the active group’s before-and-after change. Keep those quantities in separate columns when comparing claims.
Know which question the analysis answers
A treatment-policy analysis aims to describe the effect of assignment even when people discontinue treatment or use other interventions. An analysis assuming continued treatment answers another question. STEP 1 reported both types of estimates. A marketing chart that selects whichever estimate is largest can obscure a meaningful difference in what is being measured. Look for the analysis definition before treating two percentages as comparable.
Use this study-reading worksheet
| Write down | Check before comparing |
|---|---|
| Population | Diabetes status, entry criteria and relevant exclusions. |
| Regimen | Route, formulation and study dose, rather than ingredient name alone. |
| Clock | Weeks from initial assignment or from a later study phase. |
| Comparator | Placebo, another medicine or withdrawal after initial treatment. |
| Analysis | What happened after discontinuation and how missing measurements were handled. |
Do not confuse initial loss with maintenance
STEP 4 asked a maintenance question after an initial semaglutide run-in. People reaching the randomized phase either continued semaglutide or changed to placebo. Its subsequent weight changes start from that later point. They should not be placed beside an initial-treatment result as if both began with untreated participants on the same day. The run-in also selects a different group from everyone who originally started.
Translate the evidence into a useful discussion
Bring the study citation, rather than only a screenshot of its headline result. Ask which parts of the trial resemble your situation and which differ. The clinician can explain whether a different diagnosis, another medicine, tolerability or practical access changes the interpretation. Those differences deserve discussion even when the overall study is strong.
For your own review, decide in advance which observations will be useful: measured weight, the reason treatment was prescribed, side effects, function, nutrition and the ability to continue the plan. A single short interval can be difficult to interpret. Agreeing on follow-up is more useful than repeatedly checking an advertising percentage against an individual week. Trial evidence helps set informed expectations; clinical review determines how a particular course is assessed.
Sources and reading scope
- STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity
- STEP 4: Continued Weekly Semaglutide versus Placebo for Weight Loss Maintenance
Research draft prepared November 7, 2026. This is educational synthesis, not medical review or an individualized treatment recommendation. Check the linked original records and current labels before making a decision.